Tags Archives: levosimendan

Perfusfind S.L.

Abstract Objectives To evaluate the effectiveness of levosimendan in promoting weaning from veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in patients with refractory cardiogenic shock through a meta-analysis of clinical trials. Design Systematic review..

Perfusfind S.L.

Abstract Background Preliminary evidence from small, single-center studies suggests levosimendan may improve the likelihood of successful venoarterial extracorporeal membrane oxygenation (VA-ECMO) weaning in patients with cardiogenic shock. However, the literature..

Perfusfind S.L.

Abstract Objective To verify the impact of preoperative levosimendan on patients with severe left ventricular dysfunction (ejection fraction <35%) undergoing isolated coronary artery bypass grafting. Design A meta-analysis. Setting Hospitals...

Perfusfind S.L.

Abstract Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) can re-establish tissue perfusion in refractory cardiac arrest requiring cardiopulmonary resuscitation (CPR). Levosimendan showed potential benefit in VA-ECMO weaning and mortality but was not..

Perfusfind S.L.

Abstract Objectives Extracorporeal cardiopulmonary resuscitation (eCPR) is increasingly used due to its beneficial outcomes and results compared to conventional CPR. After cardiac arrest, the overall ejection fraction is severely impaired;..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) provides a temporary support system for patients with cardiogenic shock refractory to conventional medical therapies. It has been reported that levosimendan may facilitate VA-ECMO..

Perfusfind S.L.

Abstract Importance   Low cardiac output syndrome after cardiac surgery is associated with high morbidity and mortality in patients with impaired left ventricular function. Objective   To assess the ability of preoperative..

Perfusfind S.L.

Abstract Background The impact of levosimendan treatment on clinical outcome in patients undergoing extracorporeal membrane oxygenation (ECMO) support after cardiovascular surgery is unknown. We hypothesized that the beneficial effects of..

Perfusfind S.L.

Abstract Background:  We investigated if chronic levosimendan treatment can prevent and revert pressure-overload–induced right ventricular hypertrophy and failure in rats. Methods:  Right ventricular hypertrophy and failure was induced in Wistar..

Perfusfind S.L.

Abstract Background Levosimendan has been shown to confer direct renoprotection in renal endotoxemic and ischemia-reperfusion injury and could increase renal blood flow in patients with low-cardiac-output heart failure. Results from..

Perfusfind S.L.

Abstract , a , has recently emerged as a valuable agent in the peri-operative management of cardiac surgery patients. Levosimendan is a calcium-sensitising ionodilator. By binding to  C and reducing its  co-efficient, it..

Perfusfind S.L.

Abstract Background Levosimendan, a calcium sensitizer and potassium channel opener, has been demonstrated to improve myocardial function without increasing oxygen consumption and to show protective effects in other organs. Recently,..

Perfusfind S.L.

Abstract Severe postoperative complications can affect cardiac surgery patients. Levosimendan is a novel calcium sensitizer commonly administered after cardiac surgery. However, the patient benefits are controversial. PubMed, Embase, and the..

Perfusfind S.L.

Abstract Weaning failure and mortality rates in veno-arterial extracorporeal membrane oxygenation (VA-ECMO) supported patients are significant. Small studies suggest the possible usefulness of levosimendan in this environment, especially in postcardiotomy..